Mabqi is committed to delivering highly developable and functional human antibodies-based leads in various therapeutic applications and areas such as oncology, autoimmune and inflammatory diseases, …
Our tailored and integrated solution is designed to:
Our team has demonstrated its commitment to excellence and collaboration through dozens of antibody discovery and antibody maturation programs.
Unlock a new era in biotherapeutics with an antibody discovery studio—purpose-built platforms streamlining every step from target to validated candidate.
The LiteMab© Antibody Discovery Studio is designed to efficiently address a broad range of target classes, including both soluble and membrane proteins. The studio is also particularly well suited for challenging targets such as ion channels, GPCRs, peptides, proteins, and peptide–MHC complexes, enabling versatile and high-quality antibody discovery across diverse applications.
Our approach enables in vitro selection of robust and stable antibodies that bind to target antigen with high specificity. Display technologies work effectively regardless of the antigen’s form or environment, whether it’s a protein, cell, or peptide.
The LiteMab© Antibody Discovery studio delivers fully human antibody unique binders with :
Our expert team provides comprehensive solutions for antibody discovery and development programs, delivering seamless support across the entire discovery workflow.
1. Optimal antibody selection strategies:
Bio-panning strategies are performed on proteins, peptides, cells, liposomes, VLPs, …
The combination of phage and yeast display takes advantage of both platforms by starting with a vast number of antibodies in the phage display selections followed by yeast display to refine and select a diverse population of high-affinity binders (cross-reactivity, additional specificity or requested characteristics).
2. Comprehensive antibody hits’ characterization:
Comprehensive binding affinity evaluation for soluble and membrane-bound targets, EC50 binding potency assessment, cell-based flow cytometry assay to determine the binding potency based on cell line expression, epitope specificity, cross-reactivity…
3. Rigorous functional validation processes: internalization assays, direct cytotoxicity assays, fit-for-purpose functional assays, ….
Further reformatting to IgG, BsAb, ADC formats can be performed with additional in-depth profiling of antibodies.
Our versatile Antibody Discovery Studio is designed to handle both discovery and maturation programs, while seamlessly integrating multiple requirements.
This adaptability allows us to tackle a wide array of specifications, including:
For each target of interest, we perform customized antibody screening programs using our libraries of synthetic human antibodies (HuscI2TM, pHuscI2TM) and highly innovative, flexible and robust processes.
Together, let’s innovate to improve lives and advance human health!
For questions about our pipeline, accessing our LiteMab© Antibody Discovery Studio, leveraging our discovery and maturation programs, or discussing strategic partnerships, please contact us.
